Trial · NCT03017846
Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
NCT03017846, Phase 2, Completed, Steven R Cohen; results first posted 2019-01-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2. Trials, record NCT03017846. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03017846
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2
- NCT number
- NCT03017846
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Steven R Cohen
- Conditions
- Molluscum Contagiosum
- Interventions
- Cantharidin
- First posted
- 2017-01-11
- Last updated
- 2019-01-30
- Results first posted
- 2019-01-30
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Total Lesion Clearance | Assessed at each visit, until final visit on week 12 | 100% reduction in baseline lesion count |
| Secondary | Number of Subjects Who Achieve a Clearance of at Least 90% of Their Molluscum Lesions | At study completion, up to 12 weeks | |
| Secondary | Change in the Total Children's Dermatology Life Quality Index Score | Baseline (At beginning of study, before treatment) and end of study (at study completion, week 12 or at earlier visit if all lesions have cleared) | Change in the Total Children's Dermatology Life Quality Index (CDLQI) given Visit 1 prior to the first treatment and at the last study visit, up to 12 weeks. The CDLQI examines how the patient feels about the symptoms and treatment, as well as how it affects leisure, school, personal relationships, sleep, clothing choices. A total score is calculated. The total score for the CDLQI scores range: 0-1 = no effect on child's life 2-6 = small effect 7-12 = moderate effect 13-18 = very large effect 19-30 = extremely large effect |
| Secondary | Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260) | At study completion, up to 12 weeks | Comparison of the number of subjects achieving complete lesion clearance at study completion (up to 12 weeks) to the same measure obtained in our previous study (NCT02665260) |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Total Lesion Clearance | Assessed at each visit, until final visit on week 12 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Subjects Who Achieve a Clearance of at Least 90% of Their Molluscum Lesions | At study completion, up to 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Change in the Total Children's Dermatology Life Quality Index Score | Baseline (At beginning of study, before treatment) and end of study (at study completion, week 12 or at earlier visit if all lesions have cleared) | All patients who were not lost to follow-up. | score on a scale | MEAN |
| SECONDARY | Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260) | At study completion, up to 12 weeks | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Total Lesion Clearance | Cantharidin Treatment | 11 | Participants | ||
| Number of Subjects Who Achieve a Clearance of at Least 90% of Their Molluscum Lesions | Cantharidin Treatment | 14 | Participants | ||
| Change in the Total Children's Dermatology Life Quality Index Score | Cantharidin Treatment | At beginning of study, before treatment | 3.9 | Standard Deviation 5.6 | score on a scale |
| Change in the Total Children's Dermatology Life Quality Index Score | Cantharidin Treatment | At end of study | 0.38 | Standard Deviation 1.3 | score on a scale |
| Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260) | Current Study | 11 | Participants | ||
| Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260) | NCT02665260 | 7 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cantharidin Treatment | 30 | |
| Overall Study | COMPLETED | Cantharidin Treatment | 25 | |
| Overall Study | NOT COMPLETED | Cantharidin Treatment | 5 |
Source ClinicalTrials.gov
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Cantharidin Treatment | 1 | 30 | 1 |
| other | Tooth Fracture | Gastrointestinal disorders | Cantharidin Treatment | 1 | 30 | 1 |
| other | Pain | General disorders | Cantharidin Treatment | 2 | 30 | 2 |
| other | Pyrexia | General disorders | Cantharidin Treatment | 3 | 30 | 3 |
| other | Hypersensitivity | Immune system disorders | Cantharidin Treatment | 1 | 30 | 1 |
| other | Pharyngitis Streptococcal | Infections and infestations | Cantharidin Treatment | 1 | 30 | 1 |
| other | Headache | Nervous system disorders | Cantharidin Treatment | 1 | 30 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Cantharidin Treatment | 4 | 30 | 4 |
| other | Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | Cantharidin Treatment | 1 | 30 | 1 |
| other | Application Site Discoloration | Skin and subcutaneous tissue disorders | Cantharidin Treatment | 12 | 30 | 12 |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cantharidin Treatment | 0 | 30 |
| Total, other adverse events | Cantharidin Treatment | 28 | 30 |
| Total, serious adverse events | Cantharidin Treatment | 0 | 30 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Current Study vs NCT02665260: Number of Patients Achieving Complete Lesion Clearance Compared to Prior Study (NCT02665260) |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03017846
GET https://conductscience.org/api/trials/v1/NCT03017846/events?page=2